Over the last 20 years, MSD’s vaccine operations in Europe have been part of a joint venture between the companies Sanofi and MSD, called Sanofi Pasteur MSD (SPMSD).
Sanofi Pasteur MSD — owned on a 50/50 basis by Sanofi Pasteur and MSD — was created in 1994 to develop and commercialize vaccines originating from both companies’ pipelines to improve and promote public health in 19 European countries.
After carefully considering our individual strategic priorities, alongside the economic and regulatory environments for vaccine operations in the European Union, both companies mutually agreed in March of 2016 that it is in our best interests to manage our vaccine product portfolios independently.
Sanofi Pasteur and MSD believe that reintegrating their respective vaccine portfolios into their companies’ operations will better position them to drive growth, execute more efficiently, optimize vaccine coverage and bring new vaccines to market more quickly. Each company will now be able to define its own vaccines strategy to benefit public health and create value for patients, health care professionals and payers.
Throughout the year, SPMSD and its shareholders have been focused on a smooth and orderly transition while achieving their public health care goals and upholding their commitments to their employees, customers and business partners.
Following this transitional period, both companies have confirmed that Dec. 31, 2016 will be the official closing date of the end of their vaccines joint venture Sanofi Pasteur MSD (SPMSD), following clearances recently granted by the European Commission.
Dr. Maurice Hilleman b.1919 - d.2005
MSD’s long standing commitment to vaccines
Since our inception in 1891, MSD has pushed the boundaries of science with the hope and expectation that advancing scientific knowledge will lead to major advances in health.
MSD has changed the world repeatedly through our history — from the development of the first vaccines for measles and mumps and the first vaccine for HPV that causes cervical and other cancers, to the development of ground-breaking medicines for heart disease, osteoporosis, diabetes, tuberculosis, HIV and melanoma, just to name a few.
As of January 1, 2017, MSD is the point of contact for all questions related to our vaccines portfolio. For information on the MSD vaccines in your country, please visit MSD’s country overview page which will guide you to the right local MSD website.